Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) and Varex Imaging (NASDAQ:VREX – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation and institutional ownership.
Profitability
This table compares Cellectar Biosciences and Varex Imaging’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cellectar Biosciences | N/A | -349.24% | -153.18% |
| Varex Imaging | -9.64% | 8.19% | 3.63% |
Analyst Ratings
This is a summary of recent ratings and target prices for Cellectar Biosciences and Varex Imaging, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cellectar Biosciences | 1 | 0 | 3 | 0 | 2.50 |
| Varex Imaging | 1 | 1 | 2 | 1 | 2.60 |
Earnings & Valuation
This table compares Cellectar Biosciences and Varex Imaging”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cellectar Biosciences | N/A | N/A | -$21.79 million | ($6.66) | -0.38 |
| Varex Imaging | $844.60 million | 0.51 | -$70.30 million | ($2.00) | -5.15 |
Cellectar Biosciences has higher earnings, but lower revenue than Varex Imaging. Varex Imaging is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
16.4% of Cellectar Biosciences shares are held by institutional investors. 2.6% of Cellectar Biosciences shares are held by insiders. Comparatively, 4.6% of Varex Imaging shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Risk & Volatility
Cellectar Biosciences has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500. Comparatively, Varex Imaging has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500.
Summary
Varex Imaging beats Cellectar Biosciences on 8 of the 14 factors compared between the two stocks.
About Cellectar Biosciences
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
About Varex Imaging
Varex Imaging Corporation designs, manufactures, and sells X-ray imaging components. The company operates through two segments, Medical and Industrial. The Medical segment designs, manufactures, sells, and services X-ray imaging components, comprising X-ray tubes, digital detectors and accessories, ionization chambers, high voltage connectors, image-processing software and workstations, 3D reconstruction software, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, and heat exchangers. This segment's products are used in a range of applications, including CT, mammography, oncology, cardiac, surgery, dental, and other diagnostic radiography uses. The Industrial segment designs, develops, manufactures, sells, and services Linatron X-ray linear accelerators, X-ray tubes, digital detectors, high voltage connectors, and coolers for use in security and inspection applications, such as baggage screening at airports, cargo screening at ports and borders, and nondestructive testing, irradiation, and inspection in various applications. The company sells its products through imaging system original equipment manufacturers, independent service companies, and distributors, as well as directly to end-users. It has operations in North America, South America, Europe, Russia, the Middle East, India, Africa, Asia, and Australia. Varex Imaging Corporation was incorporated in 2016 and is headquartered in Salt Lake City, Utah.
Receive News & Ratings for Cellectar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
